XML 51 R33.htm IDEA: XBRL DOCUMENT v3.26.1

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Apr. 03, 2026

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):

			Fair Value						Quoted Prices in Active Markets (Level 1)						Significant Other Observable Inputs (Level 2)						Significant Unobservable Inputs (Level 3)
April 3, 2026
Assets: Foreign currency hedging contracts			$	3,480					$	—					$	3,480					$	—
Liabilities: Foreign currency hedging contracts			1,919						—						1,919						—
Liabilities: Contingent consideration			8,179						—						—						8,179
December 31, 2025
Liabilities: Foreign currency hedging contracts			$	5,221					$	—					$	5,221					$	—
Liabilities: Contingent consideration			8,179						—						—						8,179

Information regarding outstanding foreign currency forward contracts as of April 3, 2026 is as follows (dollars in thousands):

Notional Amount						Maturity Date						$/Foreign Currency												Fair Value						Balance Sheet Location
$	38,320					Apr 2027						0.0507						MXN Peso						$	3,395					Prepaid expenses and other current assets
1,543						Oct 2026						0.2421						MYR Ringgit						42						Prepaid expenses and other current assets
1,967						Oct 2026						0.0242						UYU Peso						43						Prepaid expenses and other current assets
50,362						Dec 2026						1.1826						Euro						(1,012)						Accrued expenses and other current liabilities
11,215						Apr 2027						0.0564						MXN Peso						(325)						Accrued expenses and other current liabilities
3,680						Apr 2027						0.2588						MYR Ringgit						(132)						Accrued expenses and other current liabilities
11,043						Apr 2027						0.0256						UYU Peso						(367)						Accrued expenses and other current liabilities
3,969						Jul 2027						0.0550						MXN Peso						(83)						Other long-term liabilities

Information regarding outstanding foreign currency forward contracts as of December 31, 2025 is as follows (dollars in thousands):

Notional Amount						Maturity Date						$/Foreign Currency												Fair Value						Balance Sheet Location
$	15,906					Oct 2026						1.1610						Euro						$	266					Prepaid expenses and other current assets
7,649						Oct 2026						0.0244						UYU Peso						383						Prepaid expenses and other current assets
51,699						Dec 2026						0.0501						MXN Peso						4,491						Prepaid expenses and other current assets
2,959						Oct 2026						0.2401						MYR Ringgit						82						Prepaid expenses and other current assets
3,842						Apr 2027						0.0519						MXN Peso						76						Other long-term assets
8,923						Jul 2026						1.1898						Euro						(77)						Accrued expenses and other current liabilities

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)

The following tables present the effect of cash flow hedge derivative instruments on the Company’s Condensed Consolidated Statements of Operations and Comprehensive Income for the three and three months ended April 3, 2026 and March 28, 2025 (in thousands):

						Three Months Ended
						April 3, 2026												March 28, 2025
						Total						Amount of Gain (Loss) on Cash Flow Hedge Activity						Total						Amount of Gain (Loss) on Cash Flow Hedge Activity
Sales						$	439,580					$	(116)					$	437,392					$	(583)
Cost of sales						329,985						(2,819)						317,074						(693)
Operating expenses						77,726						—						70,766						(17)

(13.)     FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

						Unrealized Gain (Loss) Recognized in OCI												Realized Gain (Loss) Reclassified from AOCI
						Three Months Ended												Location in Statements of Operations and Comprehensive  Income						Three Months Ended
						April 3, 2026						March 28, 2025												April 3, 2026						March 28, 2025
Foreign exchange contracts						$	(1,407)					$	1,808					Sales						$	(116)					$	(583)
Foreign exchange contracts						(5,096)						2,419						Cost of sales						(2,819)						(693)
Foreign exchange contracts						(92)						349						Operating expenses						—						(17)

Schedule of Estimated Fair Values for Contingent Consideration

The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for the three and three months ended April 3, 2026 and March 28, 2025 (in thousands):

			Three Months Ended
			April 3, 2026						March 28, 2025
Fair value measurement at beginning of period			$	8,179					$	904
Amount recorded for current year acquisitions			—						2,541
Fair value measurement at end of period			$	8,179					$	3,445

Schedule of Equity Method and Other Investments

Equity and other investments comprise the following (in thousands):

															April 3, 2026						December 31, 2025
Equity method investment															$	6,197					$	7,709
Non-marketable equity securities															180						180
Convertible debt instrument															13,849						—
Total equity and other investments															$	20,226					$	7,889

During the first quarter of 2026, the Company invested 12 million euro ($13.8 million) in a convertible debt instrument issued by a life sciences company that matures on December 31, 2035. The instrument has a stated interest of 4.55%, payable periodically during the term of the instrument. Depending on certain operational and financial targets, the Company may invest an additional 3 million euro under the same terms. The instrument is senior to all other indebtedness, and is secured by the assets of the investee. The Company considered guidance within ASC 815 and concluded the conversion option did not require bifurcation as an embedded derivative instrument.

The components of (Gain) loss on equity investments for each period were as follows (in thousands):

			Three Months Ended
			April 3, 2026						March 28, 2025
Equity method investment (gain) loss			$	1,468					$	(181)

Schedule of Business Combination, Contingent Consideration

The following table provides information on unpaid contingent consideration as of April 3, 2026 (in thousands):

																		As of April 3, 2026
																		Maximum Remaining Payout (undiscounted)
Acquisition						Acquisition Date						RemainingMilestone Years						2026						2027						2028						2029						Total						Fair Value
Biocoat						12/04/25						2026						$	7,000					$	—					$	—					$	—					$	7,000					$	7,000
VSi						02/28/25						2026 - 2028						—						1,000						1,000						1,000						3,000						1,179
InNeuroCo						10/01/23						2026 - 2027						—						2,700						2,700						—						5,400						—

X

- Definition

Schedule Of Equity Method And Other Investments

+ References

No definition available.

+ Details

Name:	itgr_ScheduleOfEquityMethodAndOtherInvestmentsTableTextBlock
Namespace Prefix:	itgr_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_FairValueDisclosuresAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details

Name:	us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

+ Details

Name:	us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

+ Details

Name:	us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details

Name:	us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration